We are just trying to regroup. One wrong move takes you back by four or five years,' Glenn Saldanha said, emphasising caution ...

Chairman and Managing Director Glenn Saldanha said on Monday that the company has several assets under development, including ...

Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...

But now, an Indian company has delivered a promising innovative anti-cancer drug molecule to deep-pocketed Big Pharma for ...

Ichnos Glenmark Innovation & AbbVie ink exclusive global licensing agreement for ISB 2001: New York Saturday, July 12, 2025, 12:00 Hrs [IST] IGI Therapeutics SA, a wholly owned su ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie for its early-stage blood cancer treatment.

Glenmark Pharma's exclusive licensing deal with AbbVie for ISB-2001 could be transformative, offering significant upside ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

Shares of Glenmark Pharmaceuticals Ltd ended 14.51 per cent higher on Friday after the firm announced signing an up to USD 2-billion deal with AbbVie to commmercialise its underdevelopment drug aimed ...

The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential ...

Regardless of the bearish sentiment prevailing across the Indian stock market today, Glenmark Pharma shares skyrocketed 16% ...